TKMR stock was the stock symbol for Tekmira Pharmaceuticals Corp before it changed its name to Arbutus Biopharma Corporation.
Arbutus Biopharma Corporation is a biopharmaceutical company that focuses on discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B virus (HBV) infection. The company was founded in 1992 and is headquartered in Warminster, Pennsylvania.
Arbutus Biopharma's lead product candidate, AB-729, is a subcutaneously-administered RNA interference (RNAi) therapeutic that targets HBV. The company believes that AB-729 has the potential to be a curative therapy for chronic HBV infection, which affects approximately 250 million people worldwide.
As of March 7, 2023, the market capitalization of Arbutus Biopharma Corporation was approximately $1.06 billion USD. It is important to note that investing in biopharmaceutical companies can be risky due to the nature of drug development and regulatory approval processes.
|
